[1] Marcus R. Post-menopausal osteoporosis. Best Pract Res Clin Obste Gynaecol. 2002;16(3):309-327.[2] Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. Clin Invest. 2005;115(12):3318-3325.[3] Umland EM, Rinaldi C, Parks SM, et al. The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann Pharmacother. 1999;33(12):1315-1328.[4] Ebbesen EN, Thomsen JS, Mosekilde L. Nondestructive determination of iliac crest cancellous bone strength by pQCT. Bone. 1997;21(6):535-540.[5] 王宗帅, 梁兴森, 欧阳洁,等.中西药物干预对骨质疏松大鼠骨密度和生物力学性能影响的实验研究[J].中医正骨, 2009,21(7): 491-494.[6] 鞠晓伟, 赵卫东, 李义凯.在研发防治骨质疏松药物动物实验中生物力学方法的评价[J].颈腰痛杂志, 2005, 26(4):310-312.[7] 刘忠厚,主编. 骨质疏松学[M]. 北京:科学出版社,1999: 142-143.[8] 冯涛,潘铄,刘晓辉,等.多种药物干预治疗老龄雌性骨质疏松模型大鼠股骨近端扭转实验[J]. 中国老年学杂志,2015,35(15): 4173-4174.[9] 柴勇,张敏,杨成,等.补阳还五汤联合神经干细胞移植促进脊髓损伤髓鞘再生[J].解剖学杂志,2013,36(4):785-788.[10] 杨琦,彭传刚,王野,等.4种药物干预治疗骨质疏松模型大鼠骨三点弯曲力学特性的对比分析[J]. 中国组织工程研究,2015, 19(46):7440-7444. [11] Zhang ZJ, Li YJ, Liu XG, et al. Human umbilical cord blood stem cells and brain-derived neurotrophic factor for optic nerve injury: a biomechanical evaluation. Neural Regen Res. 2015;10(7):1134-1138.[12] Wang Y, Li ZW, Luo M, et al. Biological conduits combining bone marrow mesenchymal stem cells and extracellular matrix to treat longsegment. Neural Regen Res. 2015; 10(6): 965-971. [13] Jin H, Yang Q, Ji F, et al. Human amniotic epithelial cell transplantation for the repair of injured brachial plexus nerve: evaluation of nerve viscoelastic properties. Neural Regen Res. 2015;10(2):260-265.[14] Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;5(10) : 2359-2381.[15] Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8( 1-2):136.[16] Cong E, Walker MD. The Chinese skeleton: Insights into microstructure that help to explain the epidemiology offracture. Bone Res. 2014;2(3): 14009-14011.[17] Kuijer PP, Verbeek JH, Visser B, et al. An Evidence-Based Multidisciplinary Practice Guideline to Reduce the Workload due to Lifting for Preventing Work-Related Low Back Pain. Ann Occup Environ Med. 2014;26:16.[18] 张晓刚,赵希云,宋敏,等. 骨质疏松性椎体压缩骨折的生物力学研究进展[J]. 医用生物力学,2017,32(2):199-202.[19] 周耀柱,李海龙,岳建明, 等. 氟伐他汀对去势致骨质疏松大鼠骨生物力学的影响[J]. 华西药学杂志,2015,30(1) :36-38.[20] 张庆华,朱克俭,黄敏, 等. 藤黄健骨片对骨质疏松模型大鼠干预作用实验研究[J]. 实用中医药杂志 2015,31(11):991-993.[21] 张红石,马洪顺. 雀啄回旋灸十二背俞穴对骨质疏松大鼠骨密度及骨生物力学影响的研究[J]. 南京中医药大学学报,2014,30(4): 340-343.[22] 李鹏,罗民,马洪顺. 药物治疗老龄骨质疏松大鼠骨显微结构与骨组织形态学指标的变化[J].中国老年学杂志,2014,34(140): 3975-3977.[23] Prank K, Nowlan SJ, Harms HM, et al. Time series prediction of plasma hormone concentration. Evidence for differences in predictability of parathyroid hormone secretion between osteoporotic patients and normal controls.J Clin Invest. 1995; 95(6):2910-2919.[24] Hock JM, Centrella M, Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication.Endocrinology. 1988;122(1):254-260. [25] 刘明,潘薇,陈德才. 甲状旁腺激素治疗骨质疏松症的研究进展[J].中华骨质疏松和骨矿盐疾病杂志,2012,5(2):151-155.[26] Stevenson JC, Whitehead MI, Padwick M, et al. Dietary in take of calcium and postmenopausal bone loss. Br Med J. 1988; 29(15):2012-2018. [27] 陈湜. 补肾活血法对绝经后妇女骨质疏松骨代谢的影响[D]. 广州中医药大学,2012.[28] 王宗帅, 梁兴森, 欧阳洁. 中西药物干预对骨质疏松大鼠骨密度和生物力学性能影响的实验研究[J].中医骨,2009,21(7):7491-7494. |